In recent trading session, Orchard Therapeutics plc (NASDAQ:ORTX) saw 1,144,898 shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $4.67 trading at $0.47 or 11.19% at recent trade assigns it a market valuation of $464.96 Million. That current trading price of ORTX’s stock is at a discount of -241.11% from its 52-week high price of $15.93 and is indicating a premium of 17.99% from its 52-week low price of $3.83. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 609.19 Million shares which gives us an average trading volume of 988.77 Million if we extend that period to 3-months.
For Orchard Therapeutics plc (ORTX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.6. Splitting up the data highlights that, out of 8 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 8 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.45 in the current quarter.
Orchard Therapeutics plc (NASDAQ:ORTX) trade information
Upright in the green today for gaining 11.19%, in the last five days ORTX remained trading in the green while hitting it’s week-highest on Friday, Oct 16 when the stock touched $4.97-4 price level, adding 4.43% to its value on the day. Orchard Therapeutics plc’s shares saw a change of -65.45% in year-to-date performance and have moved 8.7% in past 5-day. Orchard Therapeutics plc (NASDAQ:ORTX) showed a performance of -9.52% in past 30-days. Number of shares sold short was 3.28 Million shares which calculate 0 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $14.5 to the stock, which implies a rise of 210.49% to its current value. Analysts have been projecting $9 as a low price target for the stock while placing it at a high target of $20. It follows that stock’s current price would jump +328.27% in reaching the projected high whereas dropping to the targeted low would mean a loss of 92.72% for stock’s current value.
Orchard Therapeutics plc (ORTX) estimates and forecasts
Statistics highlight that Orchard Therapeutics plc is scoring comparatively lower than the scores of other players of the relevant industry. The company lessened -58.58% of value to its shares in past 6 months, showing an annual growth rate of 5.71% while that of industry is 14. Apart from that, the company came lowering its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to decline by -18.4% in the current quarter and calculating 4.3% increase in the next quarter. This year revenue growth is estimated to drop -55.8% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $110Million for the same. And 6 analysts are in estimates of company making revenue of $230Million in the next quarter that will end in December 01, 2020. Company posted $400Million and $595Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to drop by -72.5% while estimating it to be -61.3% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 34.7% while estimates for its earnings growth in next 5 years are of 0%
Orchard Therapeutics plc (NASDAQ:ORTX)’s Major holders
Insiders are in possession of 13.46% of company’s total shares while institution are holding 73.71% percent of that, with stock having share float percentage of 85.18%. Investors also watch the number of corporate investors in a company very closely, which is 98 institutions for Orchard Therapeutics plc that are currently holding shares of the company. FMR, LLC is the top institutional holder at ORTX for having 12.24 Million shares of worth $73.47 Million. And as of June 29, 2020, it was holding 12.59% of the company’s outstanding shares.
The second largest institutional holder is RA Capital Management, L.P., which was holding about 10.4 Million shares on June 29, 2020. The number of shares represents firm’s hold over 10.7% of outstanding shares, having a total worth of $62.42 Million.
On the other hand, Federated Hermes Kaufmann Small Cap Fund and Price (T.Rowe) New Horizons Fund are the top two Mutual Funds which own company’s shares. As of July 30, 2020, the former fund manager was holding 2500000 shares of worth $12.85 Million or 2.57% of the total outstanding shares. The later fund manager was in possession of 1.64 Million shares on June 29, 2020, making its stake of worth around $9.83 Million in the company or a holder of 1.69% of company’s stock.